Perspective Therapeutics, Inc.
CATXPerspective Therapeutics, Inc. in brief
Perspective Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. Its market value was $141 M on 30 October 2026, which makes it the 17,501st largest listed company in the world and the 3,335th largest in the USA on this site. Its shares trade under the symbol CATX (NYSE).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Perspective Therapeutics, Inc.
We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. We are also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
From the company's annual report filed with the US SEC: read the report
Perspective Therapeutics, Inc. timeline
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2005
- ✎Renamed IsoRay, Inc.Formerly Century Park Pictures Corp.
- 2023
- ✎Renamed Perspective Therapeutics, Inc.Formerly IsoRay, Inc..
Events of Perspective Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,861 (Oct 2026) · #3,339 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.7×
- Free cash flow yield
- -67.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -49.8%
- Liabilities / assets
- 22.5%
- Net debt
- $-29M
- Revenue growth
- -85.8%
- R&D / revenue
- 1490.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-114M | $-103M | — |
| Dec 2024 | — | — | $-91M | $-79M | — |
| Dec 2023 | $1M | — | $-41M | $-47M | -3252.4% |
| Dec 2022 | — | — | $-9M | $-11M | — |
| Jun 2021 | $10M | +3.8% | $-3M | $-3M | -33.7% |
| Jun 2020 | $10M | +32.4% | $-3M | $-3M | -35.6% |
| Jun 2019 | $7M | +23.5% | $-5M | $-5M | -70.3% |
| Jun 2018 | $6M | — | $-7M | $-7M | -113.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-82M | $13M | $-95M | $-1.40 | — |
| Dec 2024 | $-18M | $54M | $-73M | $-1.23 | — |
| Dec 2023 | $-37M | $1M | $-38M | $-1.74 | — |
| Dec 2022 | $-10M | $0M | $-11M | — | — |
| Jun 2021 | $-3M | $0M | $-3M | $-0.03 | — |
| Jun 2020 | $-4M | $0M | $-4M | $-0.05 | — |
| Jun 2019 | $-5M | $0M | $-5M | $-0.08 | — |
| Jun 2018 | $-6M | $0M | $-6M | $-0.12 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations · Other events
- Nov 6, 20268-KCurrent reportOther events
- Nov 6, 20268-KCurrent reportOther events
- Oct 23, 20268-KCurrent reportOther events
- Oct 8, 20268-KCurrent reportOther events
- Oct 1, 20268-KCurrent reportOther events
- Sep 14, 20268-KCurrent reportOther events
- Sep 8, 20268-KCurrent reportOther events
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations · Other events
- Aug 3, 20268-KCurrent reportOther events
Official filings of Perspective Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-114 M
- Net income
- $-103 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $267 M
- Total liabilities
- $60 M
- Total equity
- $207 M
As of December-2025
Top 100 institutional investors in Perspective Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 11,827,346 | +2,333,194 (+24.58%) | 9.79% | $33 M | Nov 13, 2026 |
| 2 | TCG Crossover Management, LLC | 7,915,567 | 0 (0.00%) | 6.55% | $22 M | Nov 16, 2026 |
| 3 | Millennium Management LLC | 6,193,174 | +1,281,319 (+26.09%) | 5.13% | $17 M | Nov 16, 2026 |
| 4 | Avidity Partners Management LP | 6,067,999 | -232,000 (-3.68%) | 5.02% | $17 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 4,407,246 | -29,326 (-0.66%) | 3.65% | $12 M | Nov 13, 2026 |
| 6 | Affinity Asset Advisors, LLC | 3,988,744 | -225,838 (-5.36%) | 3.30% | $11 M | Nov 13, 2026 |
| 7 | Citadel Advisors LLC | 3,978,908 | +173,169 (+4.55%) | 3.29% | $11 M | Nov 16, 2026 |
| 8 | Spruce Street Capital LP | 3,693,931 | 0 (0.00%) | 3.06% | $10 M | Nov 13, 2026 |
| 9 | Two Sigma Investments, LP | 2,993,831 | +1,437,380 (+92.35%) | 2.48% | $8 M | Nov 16, 2026 |
| 10 | ADAR1 Capital Management, LLC | 2,617,870 | +1,407,753 (+116.33%) | 2.17% | $7 M | Nov 16, 2026 |
| 11 | Nantahala Capital Management, LLC | 2,492,642 | -2,158,258 (-46.41%) | 2.06% | $7 M | Nov 13, 2026 |
| 12 | Geode Capital Management, LLC | 2,037,352 | -421,321 (-17.14%) | 1.69% | $6 M | Nov 6, 2026 |
| 13 | State Street Corp | 2,026,991 | -4,024,780 (-66.51%) | 1.68% | $6 M | Nov 12, 2026 |
| 14 | Nicholson Wealth Management Group, LLC | 1,618,993 | -1,000 (-0.06%) | 1.34% | $4 M | Nov 9, 2026 |
| 15 | Marshall Wace, LLP | 1,481,991 | New | 1.23% | $4 M | Nov 13, 2026 |
| 16 | UBS Group AG | 1,262,215 | +817,298 (+183.70%) | 1.05% | $3 M | Nov 10, 2026 |
| 17 | Dimensional Fund Advisors LP | 1,227,846 | +153,775 (+14.32%) | 1.02% | $3 M | Nov 4, 2026 |
| 18 | Yu Fan | 1,055,409 | 0 (0.00%) | 0.87% | $3 M | Nov 16, 2026 |
| 19 | Vanguard Portfolio Management LLC | 986,459 | -101,308 (-9.31%) | 0.82% | $3 M | Nov 13, 2026 |
| 20 | Hills Bank & Trust Co | 872,200 | 0 (0.00%) | 0.72% | $2 M | Nov 10, 2026 |
| 21 | Charles Schwab Investment Management Inc | 830,938 | +57,676 (+7.46%) | 0.69% | $2 M | Nov 16, 2026 |
| 22 | Northern Trust Corp | 781,210 | -10,564 (-1.33%) | 0.65% | $2 M | Nov 16, 2026 |
| 23 | Goldman Sachs Group Inc | 736,671 | -996,407 (-57.49%) | 0.61% | $2 M | Nov 16, 2026 |
| 24 | Morgan Stanley | 624,200 | -1,288,350 (-67.36%) | 0.52% | $2 M | Nov 13, 2026 |
| 25 | Vanguard Fiduciary Trust Co | 603,036 | +14,033 (+2.38%) | 0.50% | $2 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Voya Investment Management LLC | 453,650 | +116,149 (+34.41%) | 0.38% | $1 M | Nov 10, 2026 |
| 27 | Royal Bank Of Canada | 437,033 | +429,408 (+5631.58%) | 0.36% | $1 M | Nov 16, 2026 |
| 28 | WealthPlan Investment Management, LLC | 404,071 | 0 (0.00%) | 0.33% | $1 M | Oct 15, 2026 |
| 29 | Bank Of America Corp /de/ | 373,360 | -92,094 (-19.79%) | 0.31% | $1 M | Nov 16, 2026 |
| 30 | Wellington Management Group LLP | 370,782 | +303,337 (+449.75%) | 0.31% | $1 M | Nov 16, 2026 |
| 31 | Nuveen, LLC | 359,265 | +22,448 (+6.66%) | 0.30% | $1 M | Nov 10, 2026 |
| 32 | Bank of New York Mellon Corp | 307,636 | +9,914 (+3.33%) | 0.25% | $1 M | Nov 5, 2026 |
| 33 | Seven Fleet Capital Management LP | 296,087 | -36,526 (-10.98%) | 0.25% | $1 M | Nov 16, 2026 |
| 34 | Gsa Capital Partners LLP | 295,419 | +1,637 (+0.56%) | 0.24% | $1 M | Nov 16, 2026 |
| 35 | FMR LLC | 268,001 | -59,252 (-18.11%) | 0.22% | $1 M | Nov 10, 2026 |
| 36 | Federated Hermes, Inc. | 227,112 | +10,089 (+4.65%) | 0.19% | $1 M | Nov 12, 2026 |
| 37 | Renaissance Technologies LLC | 221,633 | +162,500 (+274.80%) | 0.18% | $1 M | Nov 12, 2026 |
| 38 | BNP Paribas Financial Markets | 220,280 | +99,391 (+82.22%) | 0.18% | $1 M | Nov 12, 2026 |
| 39 | Citigroup Inc | 214,791 | -120,126 (-35.87%) | 0.18% | $1 M | Nov 4, 2026 |
| 40 | XTX Topco Ltd | 185,404 | +153,804 (+486.72%) | 0.15% | $1 M | Nov 16, 2026 |
| 41 | Ally Bridge Group (NY) LLC | 163,634 | -580,324 (-78.00%) | 0.14% | $0 M | Nov 16, 2026 |
| 42 | American Century Companies Inc | 147,277 | +26,229 (+21.67%) | 0.12% | $0 M | Nov 12, 2026 |
| 43 | Rhumbline Advisers | 135,118 | +11,819 (+9.59%) | 0.11% | $0 M | Nov 10, 2026 |
| 44 | Bridgeway Capital Management, LLC | 133,694 | +72,894 (+119.89%) | 0.11% | $0 M | Nov 16, 2026 |
| 45 | Barclays PLC | 127,023 | +104,976 (+476.15%) | 0.11% | $0 M | Nov 6, 2026 |
| 46 | Jpmorgan Chase & Co | 126,416 | +79,278 (+168.18%) | 0.10% | $0 M | Nov 12, 2026 |
| 47 | Empowered Funds, LLC | 122,894 | New | 0.10% | $0 M | Nov 13, 2026 |
| 48 | Alliancebernstein L.P. | 109,380 | -10,650 (-8.87%) | 0.09% | $0 M | Nov 16, 2026 |
| 49 | Trueblood Wealth Management, LLC | 99,740 | 0 (0.00%) | 0.08% | $0 M | Oct 23, 2026 |
| 50 | Deutsche Bank AG\ | 88,126 | -12,631 (-12.54%) | 0.07% | $0 M | Nov 6, 2026 |
| 51 | Taylor & Morgan Wealth Management, LLC | 86,000 | +20,000 (+30.30%) | 0.07% | $0 M | Oct 9, 2026 |
| 52 | Price T Rowe Associates Inc /MD/ | 85,930 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 53 | Susquehanna International Group, LLP | 85,368 | +55,579 (+186.58%) | 0.07% | $0 M | Nov 16, 2026 |
| 54 | Panagora Asset Management Inc | 80,023 | New | 0.07% | $0 M | Nov 12, 2026 |
| 55 | State Of Wisconsin Investment Board | 71,867 | -109,995 (-60.48%) | 0.06% | $0 M | Nov 16, 2026 |
| 56 | Brevan Howard Capital Management LP | 69,292 | +55,566 (+404.82%) | 0.06% | $0 M | Nov 16, 2026 |
| 57 | Creative Planning | 64,526 | +17,645 (+37.64%) | 0.05% | $0 M | Nov 2, 2026 |
| 58 | Russell Investments Group, Ltd. | 61,012 | +21,150 (+53.06%) | 0.05% | $0 M | Nov 6, 2026 |
| 59 | MetLife Investment Management, LLC | 60,290 | -1,065 (-1.74%) | 0.05% | $0 M | Nov 16, 2026 |
| 60 | Aigen Investment Management, LP | 54,551 | +34,042 (+165.99%) | 0.05% | $0 M | Nov 16, 2026 |
| 61 | Perkins Capital Management Inc | 51,200 | +33,000 (+181.32%) | 0.04% | $0 M | Nov 2, 2026 |
| 62 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 50,105 | -10,487 (-17.31%) | 0.04% | $0 M | Nov 16, 2026 |
| 63 | HRT Financial LP | 49,219 | New | 0.04% | $0 M | Nov 13, 2026 |
| 64 | Invesco Ltd. | 49,092 | -3,774 (-7.14%) | 0.04% | $0 M | Nov 12, 2026 |
| 65 | Sykon Capital LLC | 37,932 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 66 | Auctus Advisors LLC | 37,359 | +17,015 (+83.64%) | 0.03% | $0 M | Oct 23, 2026 |
| 67 | Vanguard Global Advisers, LLC | 37,022 | +533 (+1.46%) | 0.03% | $0 M | Nov 13, 2026 |
| 68 | Police & Firemen's Retirement System of New Jersey | 35,082 | -638 (-1.79%) | 0.03% | $0 M | Nov 9, 2026 |
| 69 | Tudor Investment Corp Et Al | 33,714 | +15,608 (+86.20%) | 0.03% | $0 M | Nov 16, 2026 |
| 70 | HSBC Holdings PLC | 33,549 | +14,339 (+74.64%) | 0.03% | $0 M | Nov 16, 2026 |
| 71 | Schonfeld Strategic Advisors LLC | 28,746 | New | 0.02% | $0 M | Nov 16, 2026 |
| 72 | Manufacturers Life Insurance Company, The | 28,345 | +13 (+0.05%) | 0.02% | $0 M | Nov 13, 2026 |
| 73 | WINTON GROUP Ltd | 26,600 | New | 0.02% | $0 M | Nov 12, 2026 |
| 74 | Koa Wealth Management, LLC | 25,975 | 0 (0.00%) | 0.02% | $0 M | Oct 14, 2026 |
| 75 | Natixis | 24,382 | +18,086 (+287.26%) | 0.02% | $0 M | Nov 6, 2026 |
| 76 | Moneta Group Investment Advisors LLC | 23,707 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 77 | Wells Fargo & Company/mn | 22,081 | -64,409 (-74.47%) | 0.02% | $0 M | Nov 16, 2026 |
| 78 | Vontobel Holding Ltd. | 22,000 | 0 (0.00%) | 0.02% | $0 M | Oct 16, 2026 |
| 79 | Point72 Asset Management, L.P. | 21,260 | New | 0.02% | $0 M | Nov 16, 2026 |
| 80 | Mercer Global Advisors Inc /adv | 20,893 | -1,225 (-5.54%) | 0.02% | $0 M | Nov 16, 2026 |
| 81 | Mariner, LLC | 19,832 | New | 0.02% | $0 M | Nov 12, 2026 |
| 82 | Iowa State Bank | 19,061 | 0 (0.00%) | 0.02% | $0 M | Oct 6, 2026 |
| 83 | Simplex Trading, LLC | 17,360 | -16,580 (-48.85%) | 0.01% | $0 M | Nov 4, 2026 |
| 84 | Prudential Financial Inc | 16,610 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 85 | Provenance Wealth Advisors, LLC | 16,000 | New | 0.01% | $0 M | Oct 30, 2026 |
| 86 | HighTower Advisors, LLC | 15,625 | -174 (-1.10%) | 0.01% | $0 M | Nov 10, 2026 |
| 87 | Wealth Effects LLC | 15,000 | -20,000 (-57.14%) | 0.01% | $0 M | Oct 23, 2026 |
| 88 | ProShare Advisors LLC | 12,968 | -554 (-4.10%) | 0.01% | $0 M | Oct 29, 2026 |
| 89 | Caitong International Asset Management Co., Ltd | 12,084 | +10,744 (+801.79%) | 0.01% | $0 M | Oct 29, 2026 |
| 90 | Jump Financial, LLC | 11,841 | -49,359 (-80.65%) | 0.01% | $0 M | Nov 13, 2026 |
| 91 | Global Retirement Partners, LLC | 10,757 | +7,777 (+260.97%) | 0.01% | $0 M | Nov 10, 2026 |
| 92 | Victory Capital Management Inc | 10,537 | +109 (+1.05%) | 0.01% | $0 M | Nov 10, 2026 |
| 93 | Aquatic Capital Management LLC | 10,406 | New | 0.01% | $0 M | Nov 16, 2026 |
| 94 | New York State Common Retirement Fund | 10,300 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 95 | CIBC Bancorp USA Inc. | 10,210 | New | 0.01% | $0 M | Nov 13, 2026 |
| 96 | Cetera Investment Advisers | 10,192 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 97 | Equitable Holdings, Inc. | 10,060 | +60 (+0.60%) | 0.01% | $0 M | Nov 16, 2026 |
| 98 | Two Sigma Securities, LLC | 10,033 | New | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Legal & General Group Plc | 10,029 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 100 | Ameritas Investment Partners, Inc. | 9,372 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
Mutual funds holding Perspective Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 4.04 M | $14 M | 3.3% | 0.13% | +136% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.31 M | $11 M | 2.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.65 M | $9 M | 2.2% | 0.01% | +76% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.02 M | $3 M | 0.84% | <0.01% | +6.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 977,879 | $3 M | 0.81% | 0.02% | +84% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.13 M | $3 M | 0.93% | <0.01% | +83% | Jul 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 636,237 | $2 M | 0.53% | 0.02% | −8.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 445,775 | $2 M | 0.37% | <0.01% | +17% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 405,058 | $2 M | 0.34% | <0.01% | +39% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 319,770 | $1 M | 0.26% | <0.01% | +8.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 346,808 | $1 M | 0.29% | 0.08% | +122% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 288,380 | $1 M | 0.24% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 258,600 | $1 M | 0.21% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 269,566 | $1 M | 0.22% | <0.01% | +147% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 254,330 | $1 M | 0.21% | <0.01% | −31% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 251,300 | $1 M | 0.21% | <0.01% | +90% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 237,159 | $1 M | 0.20% | <0.01% | +87% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 168,934 | $1 M | 0.14% | <0.01% | +35% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 193,052 | $1 M | 0.16% | 0.01% | +106% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 193,329 | $1 M | 0.16% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series | 188,576 | $1 M | 0.16% | 0.07% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 136,400 | $1 M | 0.11% | 0.03% | new | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 129,409 | $1 M | 0.11% | <0.01% | +48% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 144,625 | $0 M | 0.12% | 0.02% | +87% | Jun 30, 2026 |
| 🇺🇸 Voya MI Dynamic Small Cap FundVoya Investments, LLC | 105,819 | $0 M | 0.09% | 0.22% | new | May 31, 2026 |
| 🇺🇸 Voya Small Company PortfolioVoya Investments, LLC | 117,819 | $0 M | 0.10% | 0.18% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 137,405 | $0 M | 0.11% | <0.01% | +91% | Jul 31, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 137,152 | $0 M | 0.11% | 0.08% | +37% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 112,058 | $0 M | 0.09% | 0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 87,725 | $0 M | 0.07% | 0.01% | +565% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 95,830 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 75,600 | $0 M | 0.06% | 0.01% | +80% | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 63,522 | $0 M | 0.05% | <0.01% | +1.5% | May 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 73,326 | $0 M | 0.06% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 61,780 | $0 M | 0.05% | 0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 57,911 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 47,669 | $0 M | 0.04% | 0.01% | +9.8% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 53,460 | $0 M | 0.04% | 0.01% | +100% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 53,010 | $0 M | 0.04% | <0.01% | +53% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 52,405 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 50,000 | $0 M | 0.04% | 0.12% | −50% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 47,732 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 53,471 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 49,345 | $0 M | 0.04% | <0.01% | +89% | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 48,875 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 44,085 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 30,917 | $0 M | 0.03% | 0.07% | — | Apr 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 34,788 | $0 M | 0.03% | 0.01% | +73% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 27,964 | $0 M | 0.02% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 29,450 | $0 M | 0.02% | 0.01% | +87% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 28,184 | $0 M | 0.02% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 28,063 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 27,500 | $0 M | 0.02% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 30,537 | $0 M | 0.03% | <0.01% | +2.7% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 23,054 | $0 M | 0.02% | 0.04% | +106% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 22,706 | $0 M | 0.02% | 0.01% | +92% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 21,601 | $0 M | 0.02% | 0.01% | +90% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 19,647 | $0 M | 0.02% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 21,124 | $0 M | 0.02% | <0.01% | +172% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 17,994 | $0 M | 0.01% | <0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 16,195 | $0 M | 0.01% | 0.01% | +89% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 16,118 | $0 M | 0.01% | 0.01% | +72% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 15,751 | $0 M | 0.01% | 0.01% | +98% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 14,823 | $0 M | 0.01% | <0.01% | −0.7% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 13,881 | $0 M | 0.01% | 0.01% | +68% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 13,847 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 16,052 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 12,538 | $0 M | 0.01% | 0.01% | +93% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 12,410 | $0 M | 0.01% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 13,727 | $0 M | 0.01% | <0.01% | +6.5% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 13,021 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 10,674 | $0 M | <0.01% | <0.01% | −32% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 12,094 | $0 M | 0.01% | <0.01% | +72% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 9,372 | $0 M | <0.01% | 0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 8,968 | $0 M | <0.01% | 0.02% | +79% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 7,700 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 10,428 | $0 M | <0.01% | <0.01% | −1.3% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 8,258 | $0 M | <0.01% | 0.01% | +67% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,096 | $0 M | <0.01% | <0.01% | +87% | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 7,389 | $0 M | <0.01% | 0.01% | +95% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 6,207 | $0 M | <0.01% | <0.01% | +61% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 7,299 | $0 M | <0.01% | <0.01% | +209% | Jul 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 5,998 | $0 M | <0.01% | <0.01% | −7.9% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 6,000 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 5,035 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 5,013 | $0 M | <0.01% | <0.01% | +77% | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 4,720 | $0 M | <0.01% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,954 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 5,300 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 5,020 | $0 M | <0.01% | <0.01% | +548% | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,626 | $0 M | <0.01% | <0.01% | +152% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,925 | $0 M | <0.01% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 3,920 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 2,312 | $0 M | <0.01% | <0.01% | −37% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 2,288 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,607 | $0 M | <0.01% | <0.01% | +77% | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 2,136 | $0 M | <0.01% | <0.01% | −5.0% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,850 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 2,096 | $0 M | <0.01% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,903 | $0 M | <0.01% | <0.01% | +40% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Perspective Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Robert F. Williamson IIIDirector | Buyindirect | +25,000 | $0.838 | $21 K | 53,473 | Form 4 |
| filed | Frank MorichDirector | Buy | +15,000 | $0.936 | $14 K | 30,000 | Form 4 |
| filed | Robert F. Williamson IIIDirector | Buyindirect | +18,609 | $0.840 | $16 K | 28,473 | Form 4 |
| filed | Lori A. WoodsDirector | Buy | +23,750 | $0.844 | $20 K | 28,557 | Form 4 |
| filed | Frank MorichDirector | Buy | +15,000 | $0.997 | $15 K | 15,000 | Form 4 |
| filed | Robert F. Williamson IIIDirector | Buy | +6,289 | $0.839 | $5 K | 115,271 | Form 4 |
| filed | Markus PuhlmannChief Medical Officer | Buy | +35,000 | $0.845 | $30 K | 178,542 | Form 4 |
| filed | Markus PuhlmannChief Medical Officer | Buy | +6,000 | $0.830 | $5 K | 143,542 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Perspective Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 1-for-10 reverse split
Trading halts
- 2026-10-23 12:12 UTC, code T3, resumed 15:05 UTC
- 2024-11-21 14:43 UTC, code M, resumed 14:48 UTC
Fails to deliver
- : 31,425 shares at $1.17
- : 59,588 shares at $1.19
- : 56,853 shares at $1.21
- : 28,959 shares at $2.26
- : 106 shares at $2.19
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Perspective Therapeutics, Inc. scorecard#
Passes 4 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-67.4%Free cash flow is -67.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.40 vs -1.23Diluted EPS -1.40 in fiscal 2025 against -1.23 the year before (report's currency).
- ✗Net income higher than five years earlier-$103 M-$103 M in fiscal 2025 against -$3 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$103 MNet income -$103 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-41.4%-41.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 4
- ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.17 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.01 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $29 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.6%Diluted shares up 14.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Perspective Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 | FY 2016to Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | 1.4−86.7%100% | 11+7.4%100% | 10+3.9%100% | 9.7+32.3%100% | 7.3+23.5%100% | 5.9+24.4%100% | 4.8−0.2%100% | 4.8r4.8—100% | |
| Cost of revenue | — | — | — | 6.2+25.3%57.2% | 4.9+8.3%49.1% | 4.6+6.8%47.1% | 4.3+4.6%58.3% | 4.1+4.0%68.9% | 3.9−15.5%82.4% | 4.6r4.6—97.3% | |
| Gross profit | — | — | 1.4—100% | 0r4.6−100%0.0% | 5.1−0.1%50.9% | 5.1+68.2%52.9% | 3.0+65.4%41.7% | 1.8+120%31.1% | 0.8+550%17.6% | 0.1r0.1—2.7% | |
| Research and development | 84+102%— | 42+95.4%— | 21+2407%1486% | 0.9r2.6−40.4%7.9% | 1.4+26.7%14.2% | 1.1−23.6%11.6% | 1.5−15.6%20.2% | 1.7+80.9%29.5% | 1.0+82.8%20.3% | 0.5r0.5—11.1% | |
| Selling and marketing | — | — | — | 2.8+14.9%26.0% | 2.4−18.0%24.3% | 3.0+11.1%30.7% | 2.7+0.7%36.6% | 2.7+15.2%44.9% | 2.3+70.7%48.5% | 1.4r1.4—28.4% | |
| General and administrative | 30+13.6%— | 27+26.3%— | 21+278%1469% | 5.6r6.6+18.7%51.6% | 4.7+2.6%46.7% | 4.6+9.6%47.2% | 4.2+0.2%57.0% | 4.2+6.3%70.3% | 3.9r3.9+3.5%82.3% | 3.8r3.8—79.4% | |
| Operating expenses | 114+23.9%— | 92+118%— | 42+560%2955% | 6.4r12−25.1%59.5% | 8.6−0.4%85.2% | 8.6+3.6%88.8% | 8.3−3.2%113% | 8.6+20.0%145% | 7.1+37.1%150% | 5.2r5.2—109% | |
| Operating income | −114—— | −91—— | −41—−2855% | −6.4r−7.4—−59.5% | −3.4—−34.3% | −3.5—−35.9% | −5.3—−71.8% | −6.7—−114% | −6.3—−132% | −5.1r−5.1—−107% | |
| Interest and finance income | 8.1−22.8%— | 11+1026%— | 0.9+685%65.1% | 0.1+102%1.1% | 0.1+96.7%0.6% | 0.0−72.2%0.3% | 0.1+272%1.5% | 0.0−75.4%0.5% | 0.1−45.9%2.5% | 0.2r0.2—4.6% | |
| Interest expense and finance costs | — | — | 0.1—5.9% | 0—0.0% | — | — | — | — | 0−100%0.0% | 0.0r0.0—0.0% | |
| Share of profit of associates | −0.0—— | −0.0—— | −0.0—−1.2% | 0—0.0% | — | — | — | — | — | — | |
| Other non-operating income (expense) | 9.1−12.6%— | 10+1153%— | 0.8+602%58.2% | 0.1+102%1.1% | 0.1+96.7%0.6% | 0.0−72.7%0.3% | 0.1+279%1.5% | 0.0−80.0%0.5% | 0.1−60.9%3.0% | 0.4r0.4—7.8% | |
| Income before tax | −104—— | −80—— | −40—−2797% | −6.3—−58.4% | — | — | — | — | — | — | |
| Income tax | −0.8—— | −2.1—— | −2.7—−185% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from discontinued operations | — | 0.2—— | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −103—— | −79—— | −47—−3243% | −7.3—−67.4% | −3.4—−33.7% | −3.4—−35.6% | −5.1—−70.3% | −6.7—−113% | −6.2—−129% | −4.7r−4.7—−98.8% | |
| Earnings per share, basic | -1.40—— | -1.23—— | -1.74r-0.17—— | -0.05—— | -0.03—— | -0.05—— | -0.08—— | -0.12—— | -0.11—— | -0.09—— | |
| Earnings per share, diluted | -1.40—— | -1.23—— | -1.74—— | — | -0.03—— | -0.05—— | -0.08—— | -0.12—— | -0.11—— | -0.09—— | |
| Shares, weighted average (basic) | 74+14.6%— | 64+141%— | 27r268−81.2%— | 142+36.7%— | 104+53.6%— | 68—— | — | — | — | — | |
| Shares, weighted average (diluted) | 74+14.6%— | 64+141%— | 27—— | — | 104+53.6%— | 68+0.8%— | 67+21.5%— | 55+0.3%— | 55+0.0%— | 55r55—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 31−50.3%11.5% | 62+567%18.1% | 9.2−83.5%9.4% | 56−12.4%86.7% | 64+2568%90.6% | 2.4−55.1%27.5% | 5.3+105%56.5% | 2.6r2.6−56.2%34.9% | 5.9−41.5%48.3% | 10r10—56.0% | |
| Short-term investments | 114−31.0%42.7% | 165—48.5% | 0—0.0% | 0—0.0% | — | — | — | 0.8−72.9%11.1% | 3.0+35.2%24.8% | 2.2r2.2—12.4% | |
| Receivables | 0.0−94.8%0.0% | 0.1−90.0%0.0% | 1.2−27.5%1.2% | 1.6−20.1%2.5% | 2.0−1.5%2.9% | 2.0+77.1%23.5% | 1.2−3.2%12.2% | 1.2+64.2%16.0% | 0.7+20.0%5.9% | 0.6r0.6—3.3% | |
| Inventory | — | — | — | 1.4+42.4%2.2% | 1.0+51.9%1.4% | 0.6+21.7%7.4% | 0.5+7.3%5.6% | 0.5+52.9%6.6% | 0.3−3.3%2.6% | 0.3r0.3—1.8% | |
| Other current assets | 0.0−56.8%0.0% | 0.1r0.1+80.0%0.0% | 0.0r0.0+66.7%0.0% | 0.00.0%0.0% | 0.0r0.00.0%0.0% | 0.0r0.00.0%0.3% | 0.0r0.0−6.9%0.3% | 0.0r0.0−3.3%0.4% | 0.0r0.0+11.1%0.2% | 0.0r0.0—0.1% | |
| Current assets | 148−35.8%55.6% | 231+1273%67.8% | 17−71.6%17.2% | 59−11.8%92.1% | 67+1122%95.6% | 5.5−24.7%63.3% | 7.3+34.3%77.6% | 5.4−47.1%73.1% | 10−24.5%83.9% | 14r14—75.3% | |
| Property, plant and equipment | 77+33.6%28.7% | 57+928%16.8% | 5.6+182%5.7% | 2.0+0.9%3.1% | 2.0+12.9%2.8% | 1.7+7.8%19.9% | 1.6+22.7%17.1% | 1.3+24.4%17.6% | 1.1+82.7%8.6% | 0.6r0.6—3.2% | |
| Right-of-use (leased) assets | 1.5−32.3%0.6% | 2.2+197%0.6% | 0.7+45.9%0.8% | 0.5−33.3%0.8% | 0.8−23.3%1.1% | 1.0—11.5% | — | — | — | — | |
| Goodwill | — | 0−100%0.0% | 24—24.6% | — | — | — | — | — | — | — | |
| Other intangible assets | 0.4+29.7%0.1% | 0.3−21.2%0.1% | 0.4+231%0.4% | 0.1−17.7%0.2% | 0.1−5.8%0.2% | 0.1−14.8%1.6% | 0.2−18.2%1.7% | 0.2−13.9%2.7% | 0.2+52.3%1.9% | 0.2r0.2—0.8% | |
| Investments in associates | 0.1−1.6%0.0% | 0.1−5.3%0.0% | 0.1—0.1% | — | — | — | — | — | — | — | |
| Long-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 3.0r3.0—16.4% | |
| Total assets | 267−21.7%100% | 341+248%100% | 98+51.9%100% | 64−8.5%100% | 70+709%100% | 8.7−7.7%100% | 9.4+26.4%100% | 7.5−39.2%100% | 12−32.2%100% | 18r18—100% | |
| Accounts payable | 21+98.3%7.7% | 10+49.7%3.0% | 6.9r6.1+615%7.1% | 1.0+32.3%1.5% | 0.7+11.6%1.0% | 0.7−4.2%7.5% | 0.7−50.9%7.2% | 1.4+121%18.7% | 0.6+2.9%5.1% | 0.6r0.6—3.4% | |
| Current liabilities | 29+57.3%10.7% | 18+16.4%5.3% | 16+591%16.0% | 2.3+25.8%3.5% | 1.8+14.3%2.6% | 1.6+40.5%18.1% | 1.1−38.9%11.9% | 1.8+65.9%24.6% | 1.1+1.1%9.0% | 1.1r1.1—6.0% | |
| Lease liabilities (non-current) | 1.0−29.6%0.4% | 1.4+83.1%0.4% | 0.8+205%0.8% | 0.3−51.1%0.4% | 0.5−31.9%0.7% | 0.8—8.8% | — | — | — | — | |
| Total liabilities | 60+18.9%22.5% | 50+122%14.8% | 23+618%23.2% | 3.2+5.0%4.9% | 3.0+1.1%4.3% | 3.0+70.8%34.2% | 1.7−28.2%18.5% | 2.4+45.5%32.5% | 1.7−2.0%13.6% | 1.7r1.7—9.4% | |
| Retained earnings | −335—−125% | −232—−67.9% | −152—−156% | −99—−153% | −91—−130% | −88—−1011% | −84—−897% | −79—−1064% | −73—−592% | −66r−66—−367% | |
| Shareholders' equity | 207−28.8%77.5% | 291+287%85.2% | 75+22.7%76.8% | 61−9.1%95.1% | 67+1078%95.7% | 5.7−25.5%65.8% | 7.7+52.7%81.5% | 5.0−52.6%67.5% | 11−35.4%86.4% | 16r16—90.6% | |
| Total liabilities and equity | 267−21.7%100% | 341+248%100% | 98+51.9%100% | 64−8.5%100% | 70—100% | — | 9.4+26.4%100% | 7.5−39.2%100% | 12−32.2%100% | 18r18—100% | |
| Shares outstanding | 74+5.2%— | 71+151%— | 28r282−80.2%— | 142+0.1%— | 142+106%— | 69+2.2%— | 67+19.6%— | 56+2.4%— | 55+0.0%— | 55—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.3+41.0%— | 2.3+134%— | 1.0—68.8% | — | — | — | — | — | 0.1−85.6%1.4% | 0.5r0.5—9.9% | |
| Share-based compensation | 9.0+66.4%— | 5.4+44.1%— | 3.7+244%261% | 1.1+182%10.1% | 0.4−22.0%3.8% | 0.5+17.9%5.1% | 0.4+4.0%5.7% | 0.4+8.6%6.8% | 0.4+28.3%7.8% | 0.3r0.3—6.1% | |
| Cash from operating activities | −82—— | −18—— | −37—−2574% | −7.7—−71.4% | −2.8—−28.2% | −3.6—−37.6% | −5.0—−69.0% | −5.7—−96.4% | −5.7—−120% | −3.9—−81.4% | |
| Capital expenditure | −13—— | −54—— | −1.1—−74.8% | −0.3—−2.5% | −0.4—−3.8% | −0.3—−2.8% | −0.4—−6.1% | −0.3—−5.7% | −0.5—−11.5% | −0.5r−0.5—−10.0% | |
| Intangible assets bought | — | — | −0.0—−1.3% | −0.0—−0.2% | −0.0—−0.3% | −0.0—−0.1% | −0.0—−0.2% | −0.0—−0.3% | −0.1—−2.6% | −0.0r−0.0—−0.3% | |
| Cash from investing activities | 41—— | −219−998%— | 24—1700% | −0.3—−2.6% | −0.4—−4.1% | −0.3−172%−3.0% | 0.4−78.4%5.5% | 1.9+22.8%31.4% | 1.5−82.7%31.8% | 8.8r8.8—184% | |
| Shares issued | — | 276+75671%— | 0.4—25.4% | 0—0.0% | — | — | — | 0.5—8.1% | — | 0—0.0% | |
| Cash from financing activities | 10−96.4%— | 289+36764%— | 0.8+1302%54.7% | 0.1−99.9%0.5% | 65+6407%643% | 1.0−86.5%10.3% | 7.4+1315%101% | 0.5—8.8% | −0.0−123%−0.2% | 0.0r0.0—0.8% | |
| Change in cash | −31−159%— | 52—— | −12—−820% | −7.9−113%−73.5% | 61—611% | −2.9−208%−30.3% | 2.7—37.3% | −3.3—−56.3% | −4.2−186%−88.4% | 4.9r4.9—103% | |
| Report | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | −0.0*—— | |
| Research and development | 102+58.8%— | 26+28.2%— | 22+29.6%— | 21+49.1%— | 33*+156%— | 20+69.1%— | 17+79.2%— | 14+92.3%— | 13*+82.0%— | 12—— | 9.3—— | 7.5—— | 7.1r6.1*—— | |
| General and administrative | 30−4.8%— | 8.3+7.0%— | 7.8+1.1%— | 7.0−10.9%— | 7.0*−15.7%— | 7.7+10.8%— | 7.7+39.8%— | 7.8+33.4%— | 8.2*+66.9%— | 7.0—— | 5.5—— | 5.9—— | 4.9r4.3*—— | |
| Operating expenses | 132+10.1%— | 34+22.3%— | 29+20.6%— | 28+27.9%— | 40*−11.8%— | 28+47.7%— | 24+64.5%— | 22+66.3%— | 45*+276%— | 19—— | 15—— | 13—— | 12r7.8*—— | |
| Operating income | −132—— | −34—— | −29—— | −28—— | −40*—— | −28—— | −24—— | −22—— | −45*—— | −19—— | −14—— | −13—— | −12r−7.8*—— | |
| Interest and finance income | 8.2−10.4%— | 2.0+4.1%— | 2.3+8.7%— | 2.2−7.8%— | 1.6*−39.0%— | 2.0−45.4%— | 2.2−29.8%— | 2.4+96.9%— | 2.6*+4169%— | 3.6—— | 3.1—— | 1.2—— | 0.1*—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | — | 0.0*—— | |
| Share of profit of associates | −0.0—— | 0—— | −0.0—— | 0—— | −0.0*—— | 0—— | 0—— | −0.0—— | −0.0*—— | 0—— | −0.0—— | −0.0—— | −0.0*—— | |
| Other non-operating income (expense) | 7.8−24.3%— | 1.9−0.6%— | 2.3+11.5%— | 2.1−42.8%— | 1.5*−43.0%— | 1.9−46.1%— | 2.0−33.1%— | 3.7+210%— | 2.7*+8136%— | 3.5—— | 3.0—— | 1.2—— | 0.0*—— | |
| Income before tax | — | −32—— | −27—— | — | −38*—— | −26—— | −22—— | −18—— | −42*—— | −15—— | −11—— | −12—— | −12r−7.8*—— | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | 7.8*—— | |
| Income from discontinued operations | — | — | — | — | — | — | — | 0—— | 0.2*—— | 0*—— | — | — | — | |
| Net income attributable to shareholders | −123—— | −32—— | −27—— | −26—— | −37*—— | −26—— | −21—— | −18—— | −40*—— | −15—— | −12—— | −12—— | −25*—— | |
| Earnings per share, basic | — | -0.27—— | -0.22—— | -0.25—— | — | -0.35—— | -0.29—— | -0.25—— | — | -0.21—— | -0.18—— | -0.25r-0.02—— | — | |
| Earnings per share, diluted | — | -0.27—— | -0.22—— | -0.25—— | — | -0.35—— | -0.29—— | -0.25—— | — | -0.21—— | -0.18—— | -0.25r-0.02—— | — | |
| Shares, weighted average (basic) | 121+62.5%— | 121+62.5%— | 121+62.5%— | 104+43.2%— | — | 74+5.2%— | 74+11.4%— | 72+46.1%— | — | 71—— | 67—— | 50r495—— | — | |
| Shares, weighted average (diluted) | 121+62.5%— | 121+62.5%— | 121+62.5%— | 104+43.2%— | — | 74+5.2%— | 74+11.4%— | 72+46.1%— | — | 71—— | 67—— | 50r495—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 41—11.2% | 41+53.4%11.2% | 48+68.1%12.4% | 54+21.5%13.1% | 31−50.3%11.5% | 27−88.2%9.1% | 29−88.6%9.3% | 44−68.8%13.5% | 62+567%18.1% | 226—57.9% | 252—65.3% | 142—51.1% | 9.2—9.4% | |
| Short-term investments | 161—43.9% | 161+9.0%43.9% | 188+15.8%48.1% | 217+29.7%52.8% | 114−31.0%42.7% | 147+256%50.0% | 163+298%52.4% | 167+334%50.8% | 165—48.5% | 41—10.6% | 41—10.6% | 39—13.8% | 0—0.0% | |
| Receivables | 0.0—0.0% | 0.0−92.7%0.0% | 0.3+19.6%0.1% | 0.1−25.6%0.0% | 0.0−94.8%0.0% | 0.2−17.5%0.1% | 0.2+58.5%0.1% | 0.1−92.2%0.0% | 0.1−90.0%0.0% | 0.2—0.1% | 0.1—0.0% | 1.0—0.4% | 1.2—1.2% | |
| Other current assets | 3.6—1.0% | 3.6−14.6%1.0% | 4.4+5.4%1.1% | 4.4+10.2%1.1% | 0.0−56.8%0.0% | 4.2+98.5%1.4% | 4.2+239%1.3% | 4.0+208%1.2% | 0.1r0.1+80.0%0.0% | 2.1—0.5% | 1.2—0.3% | 1.3—0.5% | 0.0r0.0—0.0% | |
| Current assets | 205—56.1% | 205+15.0%56.1% | 242+23.3%61.6% | 275+27.6%67.0% | 148−35.8%55.6% | 179−33.9%60.5% | 196−33.4%63.1% | 216+14.6%65.5% | 231+1273%67.8% | 270—69.1% | 294—76.2% | 188—67.6% | 17—17.2% | |
| Property, plant and equipment | 118—32.2% | 118+83.2%32.2% | 108+72.2%27.5% | 92+51.0%22.5% | 77+33.6%28.7% | 64+46.9%21.8% | 63+324%20.1% | 61+328%18.6% | 57+928%16.8% | 44—11.2% | 15—3.8% | 14—5.1% | 5.6—5.7% | |
| Right-of-use (leased) assets | 2.0—0.5% | 2.0+27.1%0.5% | 2.2+24.3%0.6% | 2.4+22.6%0.6% | 1.5−32.3%0.6% | 1.5−36.9%0.5% | 1.8−12.5%0.6% | 2.0+88.5%0.6% | 2.2+197%0.6% | 2.4—0.6% | 2.0—0.5% | 1.1—0.4% | 0.7—0.8% | |
| Goodwill | — | — | — | — | — | — | — | — | 0−100%0.0% | 24—6.2% | 24—6.2% | 24—8.6% | 24—24.6% | |
| Other intangible assets | — | — | — | — | 0.4+29.7%0.1% | — | — | — | 0.3−21.2%0.1% | — | — | — | 0.4—0.4% | |
| Investments in associates | — | — | — | — | 0.1−1.6%0.0% | — | — | — | 0.1−5.3%0.0% | — | — | — | 0.1—0.1% | |
| Total assets | 366—100% | 366+24.0%100% | 392+26.2%100% | 411+24.7%100% | 267−21.7%100% | 295−24.6%100% | 311−19.5%100% | 329+18.3%100% | 341+248%100% | 391—100% | 386—100% | 278—100% | 98—100% | |
| Accounts payable | 32—8.6% | 32+140%8.6% | 29+317%7.5% | 26+203%6.4% | 21+98.3%7.7% | 13−39.7%4.5% | 7.0+15.0%2.3% | 8.7+44.9%2.7% | 10+49.7%3.0% | 22—5.6% | 6.1—1.6% | 6.0—2.2% | 6.9r6.1—7.1% | |
| Current liabilities | 40—10.8% | 40+92.1%10.8% | 37+181%9.3% | 31+148%7.7% | 29+57.3%10.7% | 21−26.7%7.0% | 13+22.4%4.2% | 13−12.6%3.8% | 18+16.4%5.3% | 28—7.2% | 11—2.7% | 15—5.2% | 16—16.0% | |
| Lease liabilities (non-current) | 1.0—0.3% | 1.0+0.5%0.3% | 1.3+18.5%0.3% | 1.6+32.2%0.4% | 1.0−29.6%0.4% | 1.0−42.1%0.3% | 1.1−26.1%0.3% | 1.2+13.2%0.4% | 1.4+83.1%0.4% | 1.7—0.4% | 1.5—0.4% | 1.0—0.4% | 0.8—0.8% | |
| Total liabilities | 71—19.4% | 71+35.0%19.4% | 68+51.4%17.4% | 63+41.7%15.4% | 60+18.9%22.5% | 53−16.1%17.8% | 45+0.2%14.5% | 45−7.6%13.6% | 50+122%14.8% | 63—16.0% | 45—11.6% | 48—17.4% | 23—23.2% | |
| Retained earnings | −420—−115% | −420—−115% | −388—−98.9% | −361—−87.9% | −335—−125% | −297—−101% | −271—−87.3% | −250—−75.9% | −232—−67.9% | −192—−49.0% | −176—−45.7% | −165—−59.2% | −152—−156% | |
| Shareholders' equity | 295—80.6% | 295+21.7%80.6% | 324+21.9%82.6% | 347+22.1%84.6% | 207−28.8%77.5% | 242−26.3%82.2% | 266−22.1%85.5% | 285+23.8%86.4% | 291+287%85.2% | 328—84.0% | 341—88.4% | 230—82.6% | 75—76.8% | |
| Total liabilities and equity | 366—100% | 366+24.0%100% | 392+26.2%100% | 411+24.7%100% | 267−21.7%100% | 295−24.6%100% | 311−19.5%100% | 329+18.3%100% | 341+248%100% | 391—100% | 386—100% | 278—100% | 98—100% | |
| Shares outstanding | 114—— | 114+53.6%— | 114+53.6%— | 114+54.0%— | 74+5.2%— | 74+10.0%— | 74+10.1%— | 74−87.4%— | 71+151%— | 68—— | 67—— | 587—— | 28r282—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 4.5+51.6%— | 1.2*+53.9%— | 1.1*+55.7%— | 1.1+53.8%— | 1.0*+42.6%— | 0.8*+15.8%— | 0.7*+28.1%— | 0.7+106%— | 0.7*+135%— | 0.7*—— | 0.6*—— | 0.4—— | 0.3*—— | |
| Share-based compensation | 11+26.6%— | 3.1+45.0%— | 3.0+26.8%— | 2.6+21.7%— | 2.3*+12.1%— | 2.2+10.5%— | 2.4+309%— | 2.1+220%— | 2.1*+186%— | 2.0—— | 0.6—— | 0.7—— | 0.7*—— | |
| Cash from operating activities | −108—— | −31*—— | −21*—— | −31—— | −25*—— | −16*−584%— | −20*—— | −22−256%— | −27*—— | 3.4*—— | −8.9*—— | 14—— | −9.0*—— | |
| Capital expenditure | −31—— | −4.5*—— | −14*—— | −6.9—— | −5.1*—— | −2.0*—— | −1.0*—— | −4.7—— | −15*—— | −30*—— | −1.0*—— | −9.1—— | −0.1*—— | |
| Intangible assets bought | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Cash from investing activities | −42—— | 24*+69.6%— | 15*+252%— | −110—— | 29*—— | 14*—— | 4.3*—— | −5.6—— | −139*—— | −30*—— | −3.3*—— | −47—— | −0.1*—— | |
| Cash from financing activities | 165+1444%— | 0.2*−17.8%— | 0.1*+11.4%— | 164+1548%— | −0.0*−104%— | 0.2*−66.1%— | 0.1*−99.9%— | 10.0−94.0%— | 0.3*−2.0%— | 0.6*—— | 122*—— | 166—— | 0.4*—— | |
| Change in cash | 14—— | −7.4*—— | −5.5*—— | 23—— | 3.9*—— | −2.1*—— | −16*−114%— | −17−113%— | −165*—— | −26*—— | 110*—— | 133—— | −8.7*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Perspective Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Johan (Thijs) Spoor | $2.4 M | $2.2 M | $1.8 M | $110 |
| 2024Chief executive | $5.4 M | $2.2 M | $1.8 M | $128 |
| 2023Chief executive | $1.5 M | $1.8 M | $1.0 M | $160 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Perspective Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 1 · Shareholder vote 1 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2024 | $87 M | Private placement after listing | $50 to $250 million | 9 | equity | SEC |
| Jan 2024 | $21 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| Feb 2023 | $55 M | Private placement after listing | $50 to $250 million | 54 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Perspective Therapeutics, Inc.#
$68 K spent on lobbying the US Congress and federal agencies in 2024, most often on health issues.
- Health Issues3 reports
Lobbying firms hired in 2024
FOLEY HOAG LLP $68 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2024 | $68 K | — | 3 |
| 2023 | $90 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Perspective Therapeutics, Inc. fka IsoRay Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Perspective Therapeutics, Inc.#
4 labor condition applications certified in fiscal 2026 for 4 positions, at a median wage of $128 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Research ScientistMedical Scientists, Except Epidemiologists | 2 | $98 K |
| Chief Business Strategy OfficerGeneral and Operations Managers | 1 | $362 K |
| Senior Clinical Data ManagerClinical Data Managers | 1 | $158 K |
Where: Coralville, IA 3 · Springfield, MO 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 4 | 4 | $128 K | 4 |
| FY2025 | 4 | 4 | $125 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Perspective Therapeutics, Inc.
How Perspective Therapeutics, Inc. compares in Biotechnology
- Market cap$141 M · higher than 40% of 726
- Price / book0.7× · lower than 86% of 534
- FCF yield-67.4% · higher than 18% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Perspective Therapeutics, Inc.🇺🇸 | $141 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Perspective Therapeutics, Inc.? Verify and update this profile — free
Show Perspective Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.